Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Good Life Plus

    MCap

    GBP12m

    Last close

    GBP0.02

    ▲ 0.40 (22.86%)

    KEFI Gold and Copper

    MCap

    GBP39m

    Last close

    GBP0.01

    ▲ 0.11 (20.00%)

    OSE Immunotherapeutics

    MCap

    EUR132m

    Last close

    EUR6.14

    ▲ 0.68 (12.45%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Oryzon Genomics (BME: ORY)

Last close As at 02/07/2024

EUR1.80

▲ −0.02 (−0.99%)

Market capitalisation

EUR119m

Spanish biotech Oryzon Genomics is focused on epigenetics. Iadademstat is being explored for acute leukaemias, small-cell lung cancer (SCLC) and neuroendocrine tumours. Central nervous system (CNS) asset vafidemstat has completed several Phase IIa trials and a Phase IIb trial in borderline personality disorder, and is in a Phase IIb trial for schizophrenia.

Oryzon is among the leading clinical-stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and a potentially favourable safety/efficacy profile compared with the first-generation HDAC inhibitors.

Latest Insights

View More

Healthcare | Flash note

Oryzon Genomics — Encouraging interim update on FRIDA

Healthcare | Flash note

Oryzon Genomics — ALICE data published in The Lancet Haematology

Healthcare | Flash note

Oryzon Genomics — EC taps Oryzon for healthcare initiative

Healthcare | Update

Oryzon Genomics — Doubling down on clinical activity in 2024
testalize-me-0jE8ynV4mis-unsplash
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Carlos Buesa

    CEO

Balance Sheet

Forecast net cash (€m)

19.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (2.2) 9.5 (10.9)
Relative (0.3) 9.1 (25.1)
52 week high/low €2.2/€1.6

Financials

Oryzon’s lead assets, both inhibitors of LSD1 (an epigenetic target), are vafidemstat (CNS indications) and iadademstat (oncology). In CNS, the Phase IIb PORTICO trial (borderline personality disorder, results announced January 2024) did not meet the primary endpoint with statistical significance, but vafidemstat was favoured over placebo in all efficacy measures with statistical significance in key secondary endpoints; management plans to request an FDA end-of-Phase II meeting to discuss a potential registrational Phase III programme. The Phase IIb EVOLUTION trial (schizophrenia) is ongoing. Oryzon is also deploying a CNS personalised medicine approach with its Phase I/II HOPE trial (Kabuki syndrome), expected to start in 2024. In oncology, the ongoing FRIDA trial (AML) and planned CRADA-MSKCC/STELLAR trials (SCLC) may be pivotal; the FDA has granted Orphan Drug designation for iadademstat in these indications. FRIDA is one of Oryzon’s key strategic priorities in oncology; encouraging interim results were reported in June 2024.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2022A 15.7 (5.3) (6.3) (7.49) N/A N/A
2023A 14.2 (4.4) (6.0) (5.65) N/A N/A
2024E 12.9 (3.1) (4.1) (2.53) N/A N/A
2025E 33.7 16.9 15.4 29.08 6.2 6.1

Research

testalize-me-0jE8ynV4mis-unsplash

Flash note

Healthcare

Oryzon Genomics — ALICE data published in The Lancet Haematology
testalize-me-0jE8ynV4mis-unsplash

Flash note

Healthcare

Oryzon Genomics — EC taps Oryzon for healthcare initiative

Healthcare

Flash note

Oryzon Genomics — Encouraging interim update on FRIDA
View All

Further insights

insight

Epigenetics

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free